Csk defines the ability of integrin-mediated cell adhesion and migration in human colon cancer cells: implication for a potential role in cancer metastasis.
Progression of human colon cancer is often associated with elevated expression and activity of the Src family tyrosine kinase (SFK). SFK is ordinarily in equilibrium between inactive and primed states by a balance of negative regulatory kinase Csk and its counteracting tyrosine phosphatase(s), both of which act on the regulatory C-terminal tyrosine of SFK. To evaluate the contribution of the regulatory system of SFK in cancer progression, we here modulated the equilibrium status of SFK by introducing wild-type or dominant-negative Csk in human epithelial colon cancer cells, HCT15 and HT29. Overexpression of wild-type Csk induced decreased SFK activation, increased cell-cell contacts mediated by E-cadherin, decreased the number of focal contacts and decreased cell adhesion/migration and in vitro invasiveness. Conversely, expression of a dominant-negative Csk resulted in elevated SFK activation, enhanced phosphorylation of FAK and paxilllin, enhanced cell scattering, an increased number of focal contacts, dramatic rearrangement of actin cytoskeleton and increased cell adhesion/migration and in vitro invasiveness. In these scattered cells, however, localization, expression and phosphorylation of either E-cadherin or beta-catenin were not significantly affected, suggesting that the E-cadherin-mediated cell-cell contact is indirectly regulated by SFK. Furthermore, all these events occurred absolutely dependent on integrin-mediated cell adhesion. These findings demonstrate that Csk defines the ability of integrin-SFK-mediated cell adhesion signaling that influences the metastatic potential of cancer cells.
Rengifo-Cam
William
W
Department of Oncogene Research, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, 565-0871 Osaka, Japan.
Konishi
Akio
A
Morishita
Naoki
N
Matsuoka
Hidetada
H
Yamori
Takao
T
Nada
Shigeyuki
S
Okada
Masato
M
D000199:Actins / Q000737:chemistry; D000081247:CSK Tyrosine-Protein Kinase; D015820:Cadherins / Q000737:chemistry; D002448:Cell Adhesion; D002450:Cell Communication; D002465:Cell Movement; D003110:Colonic Neoplasms / Q000473:pathology*; D003598:Cytoskeletal Proteins / Q000737:chemistry; D006801:Humans; D016023:Integrins / Q000502:physiology*; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis / Q000473:pathology*; D010770:Phosphotransferases / Q000502:physiology*; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins / Q000502:physiology*; D015534:Trans-Activators / Q000737:chemistry; D051176:beta Catenin; D019061:src-Family Kinases / Q000502:physiology
D000199:Actins; C495270:CTNNB1 protein, human; D015820:Cadherins; D003598:Cytoskeletal Proteins; D016023:Integrins; D011518:Proto-Oncogene Proteins; D015534:Trans-Activators; D051176:beta Catenin; D010770:Phosphotransferases; D011505:Protein-Tyrosine Kinases; D000081247:CSK Tyrosine-Protein Kinase; D019061:src-Family Kinases; C000631346:CSK protein, human